Formulations for pulmonary administration of anticancer agents to treat lung malignancies

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 24, Issue 2, 2011, Pages 61-80

  Carvalho, Thiago C ^a   Carvalho, Simone R ^a   McConville, Jason T ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

chemotherapy; dosage forms; formulation; inhalation; lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CELECOXIB; CHLOROFLUOROCARBON; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DILAUROYLPHOSPHATIDYLCHOLINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FARNESOL; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; FLUOROURACIL; GEMCITABINE; ITRACONAZOLE; MACROGOL 200; METHOTREXATE; NIMESULIDE; PACLITAXEL; POLOXAMER; POLYGLACTIN; POLYGLUTAMIC ACID; POLYLACTIDE; POLYLYSINE; POLYSORBATE 80; RUBITECAN;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; COUGHING; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENDOMETRIUM CARCINOMA; FIRST PASS EFFECT; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TOXICITY; LUNG TUMOR; METASTASIS; METERED DOSE INHALER; MULTIPLE CYCLE TREATMENT; NEBULIZER; NONHUMAN; OSTEOSARCOMA; PARTICLE SIZE; POWDER INHALER; PRIMARY TUMOR; SOFT TISSUE SARCOMA; SPINDLE CELL CARCINOMA; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERUS CANCER;

ADMINISTRATION, INHALATION; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 79953893441     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0794     Document Type: Article

References (120)

1. American Cancer Society: Cancer Facts & Figures 2009. 2009.
2. American Cancer Society: Cancer Facts & Figures 2008. 2008.
3. American Cancer Society: Cancer Facts & Figures 2007. 2007.
4. Alberg AJ, and Samet JM: Epidemiology of lung cancer. Chest. 2003;123:21S-49S. (Pubitemid 36135701)
5. National Cancer Institute (NCI): Physicians data query (PDQ): small cell lung cancer treatment (health professional version), Last Update: 07/01/2009; Checked on: 02/22/2010; Available at http://www.cancer.gov/cancertopics/pdq/ treatment/small-cell-lung/healthprofessional
6. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, and Piccirillo J: Changing epi-demiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539-4544. (Pubitemid 46630948)
7. National Cancer Institute (NCI): Physician data query (pdq): non-small cell lung cancer treatment (health profes-sional version). Last Update: 02/05/2010; Checked on: 02/22/2010; Available at: http://www.cancer.gov/ cancerto-pics/pdq/treatment/non-small-cell-lung/healthprofessional.
8. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Ger-shenwald JE, Hwu P, and Zagars GK: Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006;64:106-113. (Pubitemid 41831216)
9. Chen F, Fujinaga T, Sato K, Sonobe M, Shoji T, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Toi M, and Date H: Clinical features of surgical resection for pulmonary metastasis from breast cancer. EJSO. 2009;35:393-397.
10. Mountain CF: Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-1717. (Pubitemid 27260107)
11. Simon GR, and Wagner H: Small cell lung cancer. Chest. 2003;123:259S-271S. (Pubitemid 36138804)
12. Riedel RF, and Crawford J: Small-cell lung cancer: a review of clinical trials. Semin Thorac Cardiovasc Surg. 2003;15:448-456. (Pubitemid 38100720)
13. Davies AM, Lara PN, Lau DH, and Gandara DR: Treatment of extensive small cell lung cancer. Hematol Oncol Clin N Am. 2004;18:373-385. (Pubitemid 38496473)
14. Posther KE, and Harpole DH: The surgical management of lung cancer. Cancer Invest. 2006;24:56-67 (Pubitemid 43247275)
15. Fischer S, Darling G, Pierre AF, Sun A, Leight N, Waddell TK, Keshavjee S, and de Perrot M: Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. Eur J Cardiothorac Surg. 2008;33:1129-1133.
16. Hotta K, Matsuo K, Kiura K, Ueoka H, and Tanimoto M: Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. Curr Opin Oncol. 2006;18:144-150. (Pubitemid 43740434)
17. Al Hebshi A, and Al Hadab A: An overview of radiation therapy in the treatment of non-small-cell lung cancer. Ann Thoracic Med. 2008;3:S89-S96.
18. Erridge SC, and Murray N: Thoracic radiotherapy for limited-stage small cell lung cancer: issues of timing, vol-umes, dose, and fractionation. Semin Oncol. 2003;30:26-37. (Pubitemid 36254672)
19. Faivre-Finn C, Lee LW, Lorigan P, West C, and Thatcher N: Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments. Clin Oncol. 2005;17:591-598. (Pubitemid 41700322)
20. De Ruysscher D, and Vansteenkiste J: Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother Oncol. 2000;55:1-9. (Pubitemid 30219428)
21. Warde P, and Payne D: Does thoracic irradiation improve survival and local-control in limited-stage small-cell carci-noma of the lung\a metaanalysis. J Clin Oncol. 1992;10: 890-895.
22. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoshi T, Osterlind K, Tattersall MHN, and Wagner H: A metaa-nalysis of thoracic radiotherapy for small-cell lung-cancer. N Engl J Med. 1992;327:1618-1624.
23. Kim CK, and Lim SJ: Recent progress in drug delivery systems for anticancer agents. Arch Pharm Res. 2002;25: 229-239.
24. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, and Brem H: Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007;6:609-621. (Pubitemid 351308218)
25. Partridge AH, Avorn J, Wang PS, and Winer EP: Ad-herence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652-661. (Pubitemid 34552485)
26. Hande KR: Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34:1514-1521. (Pubitemid 28446331)
27. Joel SP, Clark PI, Heap L, Webster L, Robbins S, Craft H, and Slevin ML: Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Phar-macol. 1995;37:125-133.
28. Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL, and Williams RO: Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm. 2006;63:95-102. (Pubitemid 43776206)
29. Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, and Lemarie E: Aero-solized chemotherapy. J Aerosol Med Pulm Drug Deliv. 2008;21:61-70.
30. Sharma S, White D, Imondi AR, Placke ME, Vail DM, and Kris MG: Development of inhalational agents for oncologic use. J Clin Oncol. 2001;19:1839-1847 (Pubitemid 32230887)
31. Watts AB, McConville JT, and Williams RO: Current ther-apies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm. 2008;34:913-922.
32. Son YJ, and McConville JT: Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm. 2008;34:948-959.
33. Mitchell JP, and Nagel MW: Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med-Depos Clear Eff Lung. 2003;16:341.
34. Rytting E, Nguyen J, Wang XY, and Kissel T: Biodegrad-able polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv. 2008;5:629-639. (Pubitemid 351998253)
35. Shoyele SA, and Cawthome S: Particle engineering tech-niques for inhaled biopharmaceuticals. Adv Drug Delivery Rev. 2006;58:1009-1029. (Pubitemid 44712022)
36. Phalen RF: The Respiractory Tract. In: PF Phalen (ed). In-halation Studies: Foundations and Techniques. Informa Health Care, New York; pp. 33-68, 2008.
37. Labiris NR, and Dolovich MB: Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effective-ness of aerosolized medications. Br J Clin Pharmacol. 2003; 56:588-599. (Pubitemid 37491710)
38. Newman SP, and Chan HK: In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv. 2008;21:77-84.
39. de Boer AH, Gjaltema D, Hagedoorn P, and Frijlink HW: Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction tech-nique. Int J Pharm. 2002;249:219-231. (Pubitemid 35333448)
40. Ganguly S, Moolchandani V, Roche JA, Shapiro PS, Somaraju S, Eddington ND, and Dalby RN: Phospholipid-induced in vivo particle migration to enhance pulmonary deposition. J Aerosol Med Pulm Drug Deliv. 2008;21:343-350.
41. Yi D, and Wiedmann TS: Inhalation adjuvant therapy for lung cancer. J Aerosol Med Pulm Drug Deliv. 2010;23:181-187.
42. Ruenraroengsak P, Cook JM, and Florence AT: Nanosys-tem drug targeting: Facing up to complex realities. J Con-trol Release. 2009;141:265-276.
43. Atkins PJ, Barker NP, and Mathisen D: The design and development of inhalation drug delivery systems. In: AJ Hickey (ed). Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker, Inc., New York; pp. 155-185, 1992.
44. Cryan S-A, Sivadas N and Garcia-Contreras L: In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Delivery Rev. 2007;59:1133-1151. (Pubitemid 47628783)
45. Chrystyn H: Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol. 2001;51: 289-299. (Pubitemid 32391483)
46. Dolovich MB: Practical aspects of imaging techniques em-ployed to study aerosol deposition and clearance. In: AJ Hickey (ed). Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker, Inc., New York; pp. 171-213, 1992.
47. Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, and Knight V: Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol. 1999;44:187-192. (Pubitemid 29350173)
48. Phalen RF: Animal models. In: RF Phalen, ed. Inhalation Studies: Foundations and Techniques. Informa Health Care, New York; pp. 187-214, 2008.
49. 2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol. 2001;47:451-456. (Pubitemid 32397623)
50. Koshkina NV, Waldrep JC, and Knight V: Camptothecins and lung cancer: improved delivery systems by aerosol. Curr Cancer Drug Targets. 2003;3:251-264. (Pubitemid 36944259)
51. Brown RA, and Schanker LS: Absorption of aerosolized drugs from the rat lung. Drug Metab Dispos. 1983;11: 355-360. (Pubitemid 13035486)
52. Patton JS, Fishburn CS, and Weers JG: The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1:338-344.
53. Schanker LS, and Less MJ: Lung pH and pulmonary ab-sorption of nonvolatile drugs in rat. Drug Metab Dispos. 1977;5:174-178. (Pubitemid 8321949)
54. Antineoplastic Agents (10:00). In: GK McEvoy, ed. Ameri-can Hospital Formulary Service (AHFS) Drug Information® 2010. American Society of Health-System Pharmacists, Inc., Bethesda, MD; pp. 902-1260, 2010.
55. Montharu J, Le Guellec S, Kittel B, Rabemampianina Y, Guillemain J, Gauthier F, Diot P, and de Monte M: Eva-luation of lung tolerance of ethanol, propylene glycol, and sorbitan monooleate as solvents in medical aerosols. J Aerosol Med Pulm Drug Deliv. 2010;23:41-46.
56. Vaughn JM, Wiederhold NP, McConville JT, Coalson JJ, Talbert RL, Burgess DS, Johnston KP, Williams RO, and Peters JI: Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. Int J Pharm. 2007;338: 219-224. (Pubitemid 46777243)
57. Mogalian E, and Myrdal PB: Pharmaceutical solvents for pulmonary drug delivery. In: P Augustijns, and M Brew-ster (eds). Solvent Systems and Their Selection in Pharmaceu-tics and Biopharmaceutics. Springer, AAPS Press, New York; pp. 427-441, 2007.
58. Shaik MS, Haynes A, McSween J, Ikediobi O, Kanikkannan N, and Singh M: Inhalation delivery of HFA-based metered dose anticancer agents via inhaler using methotrexate as a model drug. J Aerosol Med-Depos Clear Eff Lung. 2002;15: 261-270. (Pubitemid 34983132)
59. Haynes A, Shaik MS, Chatterjee A, and Singh M: Evalua-tion of an aerosolized selective COX-2 inhibitor as a po-tentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm Res. 2003;20:1485-1495. (Pubitemid 37164058)
60. Haynes A, Shaik MS, Chatterjee A, and Singh M: For-mulation and evaluation of aerosolized celecoxib for the treatment of lung cancer. Pharm Res. 2005;22:427-439. (Pubitemid 40558502)
61. Seedher N, and Bhatia S: Solubility enhancement of COX-2 inhibitors using various solvent systems. AAPS Pharm Sci-Tech. 2003;4:E33.
62. Emmen HH, Hoogendijk EMG, Klopping-Ketelaars WAA, Muijser H, Duistermaat E, Ravensberg JC, Alexander DJ, Borkhataria D, Rusch GM, and Schmit B: Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-heptafluoropropane) following whole-body exposure. Regul Toxicol Pharmacol. 2000;32:22-35.
63. Myrdal PB, Karlage KL, Stein SW, Brown BA, and Haynes A: Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers. J Pharm Sci. 2004;93:1054-1061. (Pubitemid 38420415)
64. Fulzele SV, Chatterjee A, Shaik MS, Jackson T, and Singh M: Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res. 2006;23:2094-2106.
65. Shaik MS, Chatterjee A, Jackson T, and Singh M: En-hancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer. 2006;118:396-404. (Pubitemid 41779079)
66. Dintaman JM, and Silverman JA: Inhibition of p-glyco-protein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 1999;16:1550-1556. (Pubitemid 29510551)
67. Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, Cantonati H, Attems J, Gsur A, and Micksche M: Multidrug resistance markers p-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications. J Cancer Res Clin Oncol. 2005;131:355-363. (Pubitemid 40674620)
68. Elhissi AMA, Faizi M, Naji WF, Gill HS, and Taylor KMG: Physical stability and aerosol properties of liposomes de-livered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm. 2007;334: 62-70. (Pubitemid 46400313)
69. Esteban E, Casillas M, and Cassinello A: Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treat Rev. 2009;35:364-373.
70. Koshkina NV, and Kleinerman ES: Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteo-sarcoma lung metastases. Int J Cancer. 2005;116:458-463. (Pubitemid 40993344)
71. Gagnadoux F, Pape AL, Lemarie E, Lerondel S, Valo I, Leblond V, Racineux JL, and Urban T: Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J. 2005;26:657-661. (Pubitemid 41448664)
72. Gagnadoux F, Le Pape A, Urban T, Montharu J, Vecellio L, Dubus JC, Leblond V, Diot P, Grimbert D, Racineux JL, and Lemarie E: Safety of pulmonary administration of gemci-tabine in rats. J Aerosol Med-Depos Clear Eff Lung. 2005; 18:198-206. (Pubitemid 40911360)
73. Gagnadoux F, Leblond V, Vecellio L, Hureaux J, Le Pape A, Boisdron-Celle M, Montharu J, Majoral C, Fournier J, Urban T, Diot P, Racineux JL, and Lemarie E: Gemcitabine aerosol: In vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Che-mother Pharmacol. 2006;58:237-244.
74. Rodriguez CO, Crabbs TA, Wilson DW, Cannan VA, Skorupski KA, Gordon N, Koshkina N, Kleinerman E, and Anderson PM: Aerosol gemcitabine: Preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv. 2010;23:197-206.
75. Stella B, Arpicco S, Rocco F, Marsaud V, Renoir JM, Cattel L, and Couvreur P: Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nano-capsules. Int J Pharm. 2007;344:71-77. (Pubitemid 47464827)
76. Pili B, Bourgaux C, Meneau F, Couvreur P, and Ollivon M: Interaction of an anticancer drug, gemcitabine, with phos-pholipid bilayers. J Therm Anal Calorim. 2009;98:19-28.
77. Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, Lobenberg R, and Roa WH: Formulation and cytotoxicity of doxoru-bicin nanoparticles carried by dry powder aerosol particles. Int J Pharm. 2006;319:155-161. (Pubitemid 44051806)
78. Rautio J, and Chikhale PJ: Drug delivery systems for brain tumor therapy. Curr Pharm Des. 2004;10:1341-1353. (Pubitemid 38559751)
79. Kato T, Yashiro T, Murata Y, Herbert DC, Oshikawa K, Bando M, Ohno S, and Sugiyama Y: Evidence that exoge-nous substances can be phagocytized by alveolar epithelial cells and transported into blood capillaries. Cell Tissue Res. 2003;311:47-51. (Pubitemid 35478223)
80. Hershey AE, Kurzman ID, Forrest LJ, Bohling CA, Stone-rook M, Placke ME, Imondi AR, and Vail DM: Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res. 1999;5:2653-2659. (Pubitemid 29437354)
81. McCallion ONM, Taylor KMG, Thomas M, and Taylor AJ: Nebulization of fluids of different physicochemical prop-erties with air-jet and ultrasonic nebulizers. Pharm Res. 1995;12:1682-1688. (Pubitemid 26004694)
82. Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, White DA, Ratain MJ, Schiller JH, Sandler A, Kraut M, Mani S, and Murren JR: Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007;13:1246-1252. (Pubitemid 46424066)
83. Kleeberger L, and Rottinger EM: Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin-A cytotoxicity for Chinese-hamster ovary cells. Cancer Chemother Pharmacol. 1993;33:144-148. (Pubitemid 23325415)
84. Lou YP, and Lundberg JM: Inhibition of low pH evoked activation of airway sensory nerves by capsazepine, a novel capsaicin-receptor antagonist. Biochem Biophys Res Com-mun. 1992;189:537-544. (Pubitemid 23030074)
85. Simonsson BG, Jacobs FM, and Nadel JA: Role of auto-nomic nervous system and cough reflex in increased re-sponsiveness of airways in patients with obstructive airway disease. J Clin Invest. 1967;46:1812.
86. Lalloo UG, Fox AJ, Belvisi MG, Chung KF, and Barnes PJ: Capsazepine inhibits cough induced by capsaicin and ci-tric-acid but not by hypertonic saline in guinea-pigs. J Appl Physiol. 1995;79:1082-1087.
87. Joo JH, Liao G, Collins JB, Grissom SF, and Jetten AM: Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response. Cancer Res. 2007;67:7929-7936. (Pubitemid 47281390)
88. Cantrell CL, Franzblau SG, and Fischer NH: Anti-mycobacterial plant terpenoids. Planta Med. 2001;67: 685-694.
89. Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P, and Nickerson KW: Quorum sensing in the dimorphic fungus Candida albicans is medi-ated by farnesol. Appl Environ Microbiol. 2001;67:2982-2992. (Pubitemid 33644762)
90. Wang Z, Chen HT, Roa W, and Finlay WH: Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J Pharm Pharm Sci. 2003;6:95-100. (Pubitemid 37207244)
91. Prokop RM, Finlay WH, and Stapleton KW: An in vitro technique for calculating the regional dosages of drugs delivered by an ultrasonic nebulizer. J Aerosol Sci. 1995; 26:847-860.
92. Nikander K, Turpeinen M, and Wollmer P: The conven-tional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med-Depos Clear Eff Lung. 1999; 12:47-53. (Pubitemid 29266597)
93. Freiberg S, and Zhu X: Polymer microspheres for controlled drug release. Int J Pharm. 2004;282:1-18. (Pubitemid 39178480)
94. Zou Y, Fu H, Ghosh S, Farquhar D, and Klostergaard J: Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin Cancer Res. 2004;10:7382-7391. (Pubitemid 39487728)
95. Gaspar MM, Bakowsky U, and Ehrhardt C: Inhaled lipo-somes-current strategies and future challenges. J Biomed Nanotechnol. 2008;4:245-257
96. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, and Knight V: Paclitaxel liposome aerosol treatment in-duces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res. 2001;7:3258-3262. (Pubitemid 32963851)
97. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, and Relling MV: Variability in human cytochrome-p450 paclitaxel metabolism. J Pharmacol Exp Ther. 1995;275: 566-575. (Pubitemid 26025545)
98. Knight V, Koshkina NV, Golunski E, Roberts LE, and Gil-bert BE: Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. Trans Am Clin Climatol Assoc. 2004;115:395-404.
99. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, and Anti-misiaris SG: Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm. 2007;67:655-666. (Pubitemid 47576612)
100. Mabrey S, and Sturtevant JM: Investigation of phase-transitions of lipids and lipid mixtures by high sensitivity differential scanning calorimetry. Proc Natl Acad Sci USA. 1976;73:3862-3866.
101. Zakharian TY, Seryshev A, Sitharaman B, Gilbert BE, Knight V, and Wilson LJ: A fullerene-paclitaxel chemo-therapeutic: synthesis, characterization, and study of bio-logical activity in tissue culture. J Am Chem Soc. 2005;127: 12508-12509. (Pubitemid 41292167)
102. 60 fullerene nanoparticles and microparticles. Toxicol Sci. 2008;101:122-131. (Pubitemid 350239016)
103. Fulzele SV, Shaik MS, Chatterjee A, and Singh M: Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549. J Pharm Pharmacol. 2006;58:327-336. (Pubitemid 43344575)
104. Hatefi A, and Amsden B: Camptothecin delivery methods. Pharm Res. 2002;19:1389-1399. (Pubitemid 35266542)
105. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, and Gilbert BE: Anticancer exffect of 9-nitrocamptothecin lipo-some aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol. 1999;44:177-186. (Pubitemid 29350172)
106. Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, and Koshkina NV: 9-nitrocamptothecin lipo-some aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci. 2000;922:151-163. (Pubitemid 32050249)
107. Gilbert BE, Seryshev A, Knight V, and Brayton C: 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal Toxicol. 2002;14:185-197 (Pubitemid 34184958)
108. Verschraegen CF, Gilbert BE, Loyer E, Huaringa A, Walsh G, Newman RA, and Knight V: Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary ma-lignancies. Clin Cancer Res. 2004;10:2319-2326. (Pubitemid 38445689)
109. Zhang L-J, Xing B, Wu J, Xu B, and Fang X-L: Biodis-tribution in mice and severity of damage in rat lungs fol-lowing pulmonary delivery of 9-nitrocamptothecin liposomes. Pulm Pharmacol Ther. 2008;21:239-246.
110. Berg E, Svensson JO, and Asking L: Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aerosol Med-Depos Clear Eff Lung. 2007;20:97-104. (Pubitemid 46870213)
111. Wittgen BPH, Kunst PWA, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicholson S, Pe-ters GJ, and Postmus PE: Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res. 2007;13:2414-2421. (Pubitemid 46698592)
112. Chou AJ, Bell MD, Mackinson C, Gupta R, Meyers PA, and Gorlick R Phase IB/IIA study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma meta-static to the lung. J Clin Oncol (Meeting Abstracts). 2007;25:9525.
113. Hitzman CJ, Elmquist WF, Wattenberg LW, and Wied-mann TS: Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of li-posomes, microspheres, and lipid coated nanoparticles. J Pharm Sci. 2006;95:1114-1126. (Pubitemid 43723169)
114. Fu YJ, Shyu SS, Su FH, and Yu PC: Development of biode-gradable co-poly(D,L-lactic/glycolic acid) microspheres for the controlled release of 5-fu by the spray drying method. Colloids and Surfaces B-Biointerfaces. 2002;25:269-279.
115. Cory J. Hitzman WFETSW: Development of a respirable, sustained release microcarrier for 5-fluorouracil II: in vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci. 2006;95:1127-1143.
116. Hitzman CJ, Wattenberg LW, and Wiedmann TS: Phar-macokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci. 2006;95:1196-1211. (Pubitemid 43874436)
117. Hansch C, Leo A, and Hoekman D: Exploring QSAR: Volume 2: Hydrophobic, Electronic, and Steric Constants. An American Chemical Society Publication, Washington, DC; 1995.
118. Avdeef A: Absorption and Drug Development: Solubility, Permeability and Charge State. John Wiley & Sons, Inc., Ho-boken, NJ; 2003.
119. Carstens MG, de Jong P, van Nostrum CF, Kemmink J, Verrijk R, De Leede LGJ, Crornmelin DJA, and Hennink WE: The effect of core composition in biodegradable olig-omeric micelles as taxane formulations. Eur J Pharm Bio-pharm. 2008;68:596-606. (Pubitemid 351318214)
120. Dhanikula AB, and Panchagnula R: Localized paclitaxel delivery. Int J Pharm. 1999;183:85-100. (Pubitemid 29257954)